UY36286A - Tratamientos médicos basados en anamorelina - Google Patents

Tratamientos médicos basados en anamorelina

Info

Publication number
UY36286A
UY36286A UY0001036286A UY36286A UY36286A UY 36286 A UY36286 A UY 36286A UY 0001036286 A UY0001036286 A UY 0001036286A UY 36286 A UY36286 A UY 36286A UY 36286 A UY36286 A UY 36286A
Authority
UY
Uruguay
Prior art keywords
anamoreline
medical treatments
based medical
treatments
anamorelin
Prior art date
Application number
UY0001036286A
Other languages
English (en)
Spanish (es)
Inventor
Mann William
Friend John
Lu Ming
Duus Elizabeth
Polvino William
Allen Suzan
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36286(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of UY36286A publication Critical patent/UY36286A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
UY0001036286A 2014-09-04 2015-09-02 Tratamientos médicos basados en anamorelina UY36286A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04

Publications (1)

Publication Number Publication Date
UY36286A true UY36286A (es) 2016-02-29

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036286A UY36286A (es) 2014-09-04 2015-09-02 Tratamientos médicos basados en anamorelina

Country Status (44)

Country Link
US (5) US9675600B2 (enExample)
EP (2) EP3590338A3 (enExample)
JP (3) JP6356907B2 (enExample)
KR (3) KR102234319B1 (enExample)
CN (5) CN107375285A (enExample)
AP (1) AP2017009772A0 (enExample)
AR (1) AR103118A1 (enExample)
AU (1) AU2015312231B2 (enExample)
BR (1) BR112017003552A2 (enExample)
CA (1) CA2959158A1 (enExample)
CL (1) CL2017000494A1 (enExample)
CO (1) CO2017003263A2 (enExample)
CR (1) CR20170121A (enExample)
CY (1) CY1122746T1 (enExample)
DK (1) DK3188599T3 (enExample)
DO (1) DOP2017000055A (enExample)
EA (1) EA035578B1 (enExample)
EC (1) ECSP17019893A (enExample)
ES (1) ES2761777T3 (enExample)
GE (2) GEP20186939B (enExample)
HR (1) HRP20192345T1 (enExample)
HU (1) HUE046894T2 (enExample)
IL (1) IL250692B (enExample)
JO (1) JO3541B1 (enExample)
LT (1) LT3188599T (enExample)
MA (1) MA40607B1 (enExample)
MD (1) MD4710C1 (enExample)
ME (1) ME03597B (enExample)
MX (1) MX361741B (enExample)
MY (1) MY187167A (enExample)
NI (1) NI201700024A (enExample)
PE (1) PE20171109A1 (enExample)
PH (1) PH12017500392B1 (enExample)
PL (1) PL3188599T3 (enExample)
PT (1) PT3188599T (enExample)
RS (1) RS59751B1 (enExample)
SG (1) SG11201701567UA (enExample)
SI (1) SI3188599T1 (enExample)
SV (1) SV2017005400A (enExample)
TN (1) TN2017000040A1 (enExample)
TW (1) TWI639429B (enExample)
UA (1) UA120765C2 (enExample)
UY (1) UY36286A (enExample)
WO (1) WO2016036598A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
JP7854809B2 (ja) 2019-08-30 2026-05-07 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法
AU2020372131B2 (en) * 2019-10-24 2025-10-30 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
JPWO2025004650A1 (enExample) * 2023-06-28 2025-01-02

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007523048A (ja) * 2003-08-06 2007-08-16 ガストロテック・ファルマ・アクティーゼルスカブ 分泌促進物質の使用
US20050261201A1 (en) 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP2854810A4 (en) * 2012-05-25 2016-04-06 Raqualia Pharma Inc GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료

Also Published As

Publication number Publication date
CA2959158A1 (en) 2016-03-10
CN113577074A (zh) 2021-11-02
SG11201701567UA (en) 2017-03-30
KR20210035923A (ko) 2021-04-01
AR103118A1 (es) 2017-04-19
ES2761777T3 (es) 2020-05-21
NZ729673A (en) 2023-09-29
CO2017003263A2 (es) 2017-07-28
SV2017005400A (es) 2017-04-20
EP3188599A1 (en) 2017-07-12
JO3541B1 (ar) 2020-07-05
WO2016036598A1 (en) 2016-03-10
KR20180085047A (ko) 2018-07-25
LT3188599T (lt) 2019-12-10
US20170296526A1 (en) 2017-10-19
JP2018154655A (ja) 2018-10-04
PT3188599T (pt) 2020-01-15
AP2017009772A0 (en) 2017-02-28
EP3590338A2 (en) 2020-01-08
US10278964B2 (en) 2019-05-07
PL3188599T3 (pl) 2020-06-01
CN113577073A (zh) 2021-11-02
RS59751B1 (sr) 2020-02-28
DOP2017000055A (es) 2017-08-15
TWI639429B (zh) 2018-11-01
KR102307275B1 (ko) 2021-09-30
CN107205389A (zh) 2017-09-26
JP2017526695A (ja) 2017-09-14
US9675600B2 (en) 2017-06-13
EP3590338A3 (en) 2020-03-18
MX361741B (es) 2018-12-14
JP6356907B2 (ja) 2018-07-11
PH12017500392A1 (en) 2017-07-17
TN2017000040A1 (en) 2018-07-04
EP3188599B1 (en) 2019-10-02
MD4710B1 (ro) 2020-09-30
UA120765C2 (uk) 2020-02-10
JP7044918B2 (ja) 2022-03-30
US10894041B2 (en) 2021-01-19
CL2017000494A1 (es) 2017-09-15
US20160067236A1 (en) 2016-03-10
MA40607B1 (fr) 2019-11-29
US20190175574A1 (en) 2019-06-13
US20240024303A1 (en) 2024-01-25
GEAP201814459A (en) 2018-09-10
IL250692B (en) 2019-05-30
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
EP3188599A4 (en) 2017-10-11
MD4710C1 (ro) 2021-04-30
US11723902B2 (en) 2023-08-15
AU2015312231B2 (en) 2017-10-19
CN107375285A (zh) 2017-11-24
CR20170121A (es) 2017-07-17
US20210093627A1 (en) 2021-04-01
PH12017500392B1 (en) 2018-08-31
KR101881264B1 (ko) 2018-07-23
KR20170047372A (ko) 2017-05-04
ME03597B (me) 2020-07-20
JP2021080281A (ja) 2021-05-27
CY1122746T1 (el) 2021-03-12
NI201700024A (es) 2017-07-18
IL250692A0 (en) 2017-04-30
HUE046894T2 (hu) 2020-04-28
MD20170025A2 (ro) 2017-07-31
AU2015312231A1 (en) 2017-03-23
BR112017003552A2 (pt) 2017-12-05
ECSP17019893A (es) 2017-05-31
HRP20192345T1 (hr) 2020-03-20
MY187167A (en) 2021-09-07
KR102234319B1 (ko) 2021-04-01
CN109172575A (zh) 2019-01-11
TW201613587A (en) 2016-04-16
PE20171109A1 (es) 2017-08-07
JP6923486B2 (ja) 2021-08-18
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
MX2017002825A (es) 2017-09-28
SI3188599T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
IL249065A0 (en) Combination therapies for the treatment of cancer
IL255261A0 (en) Methods for treating cancer
ECSP17073743A (es) Moduladores de k-ras
PL3288581T3 (pl) Sposób leczenia nowotworu
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
IL258521B1 (en) Combination therapy for the treatment of cancer
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
DK3157527T3 (da) Ezh2-hæmmere til lymfombehandling
BR112017008399A2 (pt) abordagem de imunoterapia de combinação para tratamento de câncer
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
HUE038541T2 (hu) Rák kezelési módszerek
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
PT3134119T (pt) Tratamento do cancro
PL3393468T3 (pl) Metody leczenia niedoboru odporności
IL246558A0 (en) Novel methods for treating cancer
IL254825A0 (en) Methods of treatment with taselisib

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230427